Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Non-Current Liabilities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Other Non-Current Liabilities data on record, last reported at $4.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 16.41% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 16.41%, while the annual FY2025 figure was $4.0 million, 16.41% up from the prior year.
  • Other Non-Current Liabilities reached $4.0 million in Q4 2025 per CLDX's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $10.5 million in Q1 2022 and bottomed at $2.5 million in Q1 2025.
  • Average Other Non-Current Liabilities over 5 years is $4.9 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 60.93% in 2021, then skyrocketed 71.14% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $7.4 million in 2021, then dropped by 27.48% to $5.3 million in 2022, then dropped by 17.44% to $4.4 million in 2023, then decreased by 21.12% to $3.5 million in 2024, then grew by 16.41% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $4.0 million in Q4 2025, $2.5 million in Q3 2025, and $2.5 million in Q2 2025.